Study Designs in Osteoporosis

Journal of Bone and Mineral Research

Volumn 18, Issue 6, 2003, Pages 1129-1132

  Temple, Robert J ^a  

^a Center for Drug Evaluation and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM ANTAGONIST; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CHOICE; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; HUMAN; MEDICAL ETHICS; METHODOLOGY; MONOTHERAPY; OSTEOPOROSIS; OUTCOMES RESEARCH; QUALITY CONTROL;

COMBINED MODALITY THERAPY; CONTROLLED CLINICAL TRIALS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PLACEBOS; RESEARCH DESIGN;

EID: 0142027576     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.6.1129     Document Type: Conference Paper

References (4)

1. International Conference on Harmonization, Guidance for Industry: E-10 Choice of control group and related issues in clinical trials. Available online at http:/www.fda.gov/cder/guidance/index.htm. Accessed on March 28, 2003.
2. Temple R, Ellenberg S 2000 Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 133:455-463.
3. Lewis JA, Jonsson B, Kreutz G, Sampaio C, van Zwieten-Boot B 2002 Placebo-controlled trials and the Declaration of Helsinki. Lancet 359:1337-1340.
4. Kanis JA, Oden A, Johnell O, Caulin F, Bone H, Alexandre J-M, Abadie E, Lekkerkerker F 2002 Uncertain future of trials in osteoporosis. Osteoporos Int 13:443-449.